SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Biomarker tests of progression from tuberculosis infection to disease: a systematic review.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a global health threat, with millions of new infections annually. While most infected individuals remain asymptomatic, a subset progresses to active disease. Effective tests predicting TB progression are urgently needed to enhance prevention strategies and reduce the global TB burden.
objectiveTo evaluate biomarker-based tests designed to predict progression from TB infection to active disease.
methodsWe conducted a systematic literature search of four electronic databases for studies published between 2016, when the first trial evaluating biomarker-based tests for TB progression was published, and 2024. Quality assessment was performed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). Data on study design, population, biomarkers, and diagnostic accuracy were extracted and synthesised narratively.
results19 studies were included, reporting 70 biomarker-based tests for predicting TB progression. These included 23 gene signatures, 14 protein signatures and 33 cytokines/chemokines. Heterogeneity in study populations, methodologies and outcome definitions precluded direct comparisons. Many studies lacked transparency in reporting key population characteristics, reference standards and diagnostic accuracy outcomes, limiting clinical applicability. Most tests demonstrated only moderate predictive accuracy, with no single biomarker approach emerging as a definitive tool for clinical use.
conclusionsNo biomarker-based test to predict TB progression is currently ready for clinical implementation. Standardised methodologies, larger validation studies and improved reporting transparency are necessary to advance TB diagnostics and improve early detection efforts. Future research should prioritise refining tests for TB progression by improving their predictive accuracy, identifying appropriate target populations and evaluating their cost-effectiveness and feasibility for integration into TB prevention programmes, particularly in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.